Cancer Cachexia - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Cancer Cachexia - Pipeline Review, H2 2016’, provides an overview of the Cancer Cachexia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Cachexia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Cachexia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia

The report reviews pipeline therapeutics for Cancer Cachexia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cancer Cachexia therapeutics and enlists all their major and minor projects

The report assesses Cancer Cachexia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cancer Cachexia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acacia Pharma Limited

Aeterna Zentaris Inc.

Aphios Corporation

Atara Biotherapeutics, Inc.

Eli Lilly and Company

Helsinn Healthcare S.A.

Incyte Corporation

Lakewood-Amedex Inc

Novartis AG

Obexia ...

Acacia Pharma Limited

Aeterna Zentaris Inc.

Aphios Corporation

Atara Biotherapeutics, Inc.

Eli Lilly and Company

Helsinn Healthcare S.A.

Incyte Corporation

Lakewood-Amedex Inc

Novartis AG

Obexia AG

PsiOxus Therapeutics Limited

RaQualia Pharma Inc.

Viking Therapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Cancer Cachexia ...

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Cancer Cachexia Overview 9

Therapeutics Development 10

Pipeline Products for Cancer Cachexia - Overview 10

Pipeline Products for Cancer Cachexia - Comparative Analysis 11

Cancer Cachexia - Therapeutics under Development by Companies 12

Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes 14

Cancer Cachexia - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Cancer Cachexia - Products under Development by Companies 18

Cancer Cachexia - Products under Investigation by Universities/Institutes 19

Cancer Cachexia - Companies Involved in Therapeutics Development 20

Acacia Pharma Limited 20

Aeterna Zentaris Inc. 21

Aphios Corporation 22

Atara Biotherapeutics, Inc. 23

Eli Lilly and Company 24

Helsinn Healthcare S.A. 25

Incyte Corporation 26

Lakewood-Amedex Inc 27

Novartis AG 28

Obexia AG 29

PsiOxus Therapeutics Limited 30

RaQualia Pharma Inc. 31

Viking Therapeutics, Inc. 32

Cancer Cachexia - Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Combination Products 34

Assessment by Target 35

Assessment by Mechanism of Action 38

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

(formoterol fumarate + megestrol acetate) - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

anamorelin hydrochloride - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

ATA-842 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

AUSRM-057 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

bimagrumab - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

DLN-101 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

dronabinol - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

espindolol - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

EXT-400 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Foxo1-nRNA - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

HM-03 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

landogrozumab - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

macimorelin acetate - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

OBX-1201 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

RQ-00433412 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

ruxolitinib phosphate - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Synthetic Peptide to Antagonize Melanocortin Receptor for Cancer Cachexia - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Synthetic Peptides for Cancer Cachexia - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

tertomotide - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

VK-5211 - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Cancer Cachexia - Dormant Projects 92

Cancer Cachexia - Discontinued Products 94

Cancer Cachexia - Product Development Milestones 95

Featured News & Press Releases 95

Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer 95

Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology 96

Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology 98

Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102 99

Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 100

Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 100

Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 101

Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study 102

Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia 102

Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102 103

Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 104

Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June 105

Dec 15, 2005: Sapphire Therapeutics, Inc.’s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia 105

Jan 10, 2005: Rejuvenon's RC-1291 Ghrelin Mimetic Receives Fast Track Designation From FDA for Cancer Anorexia/Cachexia 106

Appendix 107

Methodology 107

Coverage 107

Secondary Research 107

Primary Research 107

Expert Panel Validation 107

Contact Us 107

Disclaimer 108

List of Tables

List of Tables

Number of Products under Development for Cancer Cachexia, H2 2016 10

Number of Products under Development for Cancer Cachexia - Comparative Analysis, ...

List of Tables

Number of Products under Development for Cancer Cachexia, H2 2016 10

Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Cancer Cachexia - Pipeline by Acacia Pharma Limited, H2 2016 20

Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H2 2016 21

Cancer Cachexia - Pipeline by Aphios Corporation, H2 2016 22

Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H2 2016 23

Cancer Cachexia - Pipeline by Eli Lilly and Company, H2 2016 24

Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2016 25

Cancer Cachexia - Pipeline by Incyte Corporation, H2 2016 26

Cancer Cachexia - Pipeline by Lakewood-Amedex Inc, H2 2016 27

Cancer Cachexia - Pipeline by Novartis AG, H2 2016 28

Cancer Cachexia - Pipeline by Obexia AG, H2 2016 29

Cancer Cachexia - Pipeline by PsiOxus Therapeutics Limited, H2 2016 30

Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H2 2016 31

Cancer Cachexia - Pipeline by Viking Therapeutics, Inc., H2 2016 32

Assessment by Monotherapy Products, H2 2016 33

Assessment by Combination Products, H2 2016 34

Number of Products by Stage and Target, H2 2016 36

Number of Products by Stage and Mechanism of Action, H2 2016 39

Number of Products by Stage and Route of Administration, H2 2016 42

Number of Products by Stage and Molecule Type, H2 2016 44

Cancer Cachexia - Dormant Projects, H2 2016 92

Cancer Cachexia - Dormant Projects (Contd..1), H2 2016 93

Cancer Cachexia - Discontinued Products, H2 2016 94

List of Figures

List of Figures

Number of Products under Development for Cancer Cachexia, H2 2016 10

Number of Products under Development for Cancer Cachexia - Comparative Analysis, ...

List of Figures

Number of Products under Development for Cancer Cachexia, H2 2016 10

Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 33

Number of Products by Top 10 Targets, H2 2016 35

Number of Products by Stage and Top 10 Targets, H2 2016 35

Number of Products by Top 10 Mechanism of Actions, H2 2016 38

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 38

Number of Products by Routes of Administration, H2 2016 41

Number of Products by Stage and Routes of Administration, H2 2016 41

Number of Products by Molecule Types, H2 2016 43

Number of Products by Stage and Molecule Types, H2 2016 43

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports